LAUSR

dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677. [5] Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3): 291–299. [6] Walter RB, Appelbaum FR, Tallman MS, et al. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood. 2010;116(14):2420–2428. [7] Mandrekar SJ, Dahlberg SE, Simon R. Improving clinical trial efficiency: thinking outside the box. Am Soc Clin Oncol Educ Book. 2015;35:e141–e147. [8] Berry DA. Emerging innovations in clinical trial design. Clin Pharmacol Ther. 2016;99(1):82–91. [9] Ventz S, Alexander BM, Parmigiani G, et al. Designing clinical trials that accept new arms: an example in metastatic breast cancer. JCO. 2017;35:3160–3168. [10] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. [11] Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013;122(8):1384–1394. [12] Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia. 2013;27(1):75–81. [13] Schlenk RF, D€ ohner H, D€ ohner K, et al. Event-free survival is a surrogate for overall survival in patients treated for acute myeloid leukemia [abstract]. Blood. 2015;126:3744. [14] Othus M, van Putten W, L€ owenberg B, et al. Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. Haematologica. 2016;101(7):e284–e286.